Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique

[fr] Le traitement oral du diabète de type 2 (DT2) s’est fortement diversifié au cours de la dernière décennie, avec la commercialisation d’abord des glitazones, puis des gliptines, et, enfin, tout récemment, des gliflozines. Pourtant, les deux antidiabétiques oraux développés il y a plus de 50 ans, la metformine et les sulfamides hypoglycémiants, restent les leaders du marché. Après la metformine, le choix des médicaments antidiabétiques est problématique, et doit se faire en fonction d’une évaluation de la balance bénéfices/risques, en intégrant le coût du traitement, et en favorisant une approche individuelle centrée sur le patient diabétique. Cette stratégie est celle recommandée dans la publication conjointe de l’American Diabetes Association (ADA) et de l’European Association for the Study of Diabetes (EASD), actualisée en janvier 2015. Si les grands principes du traitement du DT2 sont universels, des particularités doivent sans doute être discutées en fonction des situations régionales, et le continent Africain présente certainement des particularités à cet égard.
[en] Oral therapy of type 2 diabetes (T2D) is becoming increasingly complex during the last decade, with first the launch of glitazones, then that of gliptins and finally, very recently, that of gliflozins. However, the two oral glucose-lowering agents developed more than 50 years ago, metformin and sulfonylureas, still remain the leaders in the market. After failure of metformin monotherapy, the choice of antidiabetic medications is difficult and should be made taking into account the benefit-risk balance, with a special attention to cost of therapy and a focus on a patient-centered approach. This strategy is recommended in the recently updated joint ADA-EASD position statement, in January 2015. If the main principles of T2D therapy are universal, particularities should probably be discussed regarding regional situations, and the African continent obviously presents specificities in this respect.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Language :

French

Title :

Antidiabétiques oraux dans le traitement du diabète de type 2 : perspectives historique et médico-économique

Alternative titles :

[en] Oral antidiabetic agents in the treatment of type 2 diabetes: Historical, clinical, and economical perspectives

Publication date :

2015

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Masson, Issy-les-Moulineaux, France

Volume :

Issue :

Pages :

186-197

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

http://www.elsevier-masson.fr/medecine-des-maladies-metaboliques-1957-2557.html

Available on ORBi :

since 31 March 2015

Statistics

Number of views

144 (14 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
Erratum in: Diabetologia 2013;56:680].
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
Erratum in: Lancet 1999;354:602].
Halimi S. Do not forget that type 2 diabetes does not only expose to cardiovascular complications. Diabetes Metab 2014;40:167-8.
Scheen AJ, Charbonnel B. Effects of glucoselowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014;40:176-85.
Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-17
Erratum in: Lancet 2014;383:2212.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013;39:179-90.
Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab 2014;20:953-66.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
Erratum in: Lancet 1998;352:1558].
Boussageon R, Gueyffier F, Cornu C. Effects of pharmacological treatments on micro-and macrovascular complications of type 2 diabetes: what is the level of evidence Diabetes Metab 2014;40:169-75.
Beck E, Scheen AJ. Quels bénéfices antitumoraux attendre de la metformine Ann Endocrinol (Paris) 2013;74:137-47.
Loubatieres-Mariani MM. La découverte des sulfamides hypoglycémiants. J Soc Biol 2007;201:121-5.
Henquin JC. The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work Diabetologia 1992;35:907-12.
Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-10.
Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
Erratum in: N Engl J Med 2007;356:1387-8.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
Zoungas S, Chalmers J, Neal B, et al; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014;371:1392-406.
Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-76.
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-53.
Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-8.
Scheen AJ. Comment je traite .. Le choix entre un sulfamide hypoglycémiant et une gliptine pour traiter le diabète de type 2. Rev Med Liège 2014;69:476-84.
Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia 2004;47:969-75; discussion 976-7.
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
Erratum in: N Engl J Med 2007;357:100.
Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
Scheen AJ. Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 2012;98:175-86.
Home PD, Pocock SJ, Beck-Nielsen H, et al; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35.
Turner RM, Kwok CS, Chen-Turner C, et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78:258-73.
Scheen AJ. A review of gliptins in 2011. Expert Opin Pharmacother 2012;13:81-99.
Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother 2015;16:43-62.
Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician Ann Endocrinol (Paris) 2013;74:515-22.
Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 2012;38:89-101.
Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529-50.
Scheen AJ. Cardiovascular effects of gliptins. Nature Rev Cardiol 2013;10:73-84.
Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008;359:1092-5.
Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35.
Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med 2013;125:7-20.
Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014;370:794-7
Erratum in: N Engl J Med 2014;370:2253.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015;75:33-59.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225-36.
Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion A critical analysis. Diabetologia 2010;53:1258-69.
Grant RW, Kirkman MS. Trends in the evidence level for the American Diabetes Association's «Standards of Medical Care in Diabetes» from 2005 to 2014. Diabetes Care 2015;38:6-8.
Morgan CL, Mukherjee J, Jenkins-Jones S et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab 2014;16:977-83.
Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes Yes, they continue to serve us well! Diabetes Care 2015;38:166-9.
Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes No, it's time to move on! Diabetes Care 2015;38:170-5.
Nathan DM, Buse JB, Kahn SE, et al; GRADE Study Research Group. Rationale and design of the Glycemia Reduction Approaches in Diabetes: a comparative effectiveness study (GRADE). Diabetes Care 2013;36:2254-61.
Charbonnel B, DeFronzo R, Davidson J, et al; PROactive investigators. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010;95:2163-71.